Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin.
Activated protein C (APC) is a multi-modular anticoagulant serine protease, which degrades factor V/Va and factor VIIIa. Human APC (hAPC) is inhibited by human alpha 1-antitrypsin (AAT), while the bovine enzyme (bAPC) is fully resistant to this serpin. Structural features in the catalytic domains between the two species cause this difference, but detailed knowledge about the causal molecular difference is missing. To gain insight into the APC-AAT interaction and to create a human protein C resistant to AAT inhibition, we have used molecular modeling and site-directed mutagenesis. First, a structural model for bAPC based on the Gla-domainless X-ray structure of hAPC was built. Screening the molecular surface of the human and bovine APC enzymes suggested that a hAPC molecule resistant to AAT inhibition could be constructed by substituting only a few amino acids. We thus produced recombinant hAPC molecules with a single mutation (S173E, the numbering follows the chymotrypsinogen nomenclature), two mutations (E60aS/S61R) or a combination of all these substitutions (E60aS/S61R/S173E). Amidolytic and anticoagulant activities of the three mutant APC molecules were similar to those of wild-type hAPC. Inhibition of wild-type hAPC by AAT was characterized by a second-order rate constant (k2) of 2.71 M-1 s-1. The amino acid substitution at position 173 (S173E mutant) led to partial resistance to AAT (k2 = 0.84 M-1 s-1). The E60aS/S61R mutant displayed mild resistance to AAT inhibition (k2 = 1.70 M-1 s-1), whereas the E60aS/S61R/S173E mutant was inefficiently inactivated by AAT (k2 = 0.40 M-1 s-1). Inhibition of recombinant APC molecules by the serpin protein C inhibitor (PCI) in the presence and absence of heparin was also investigated.
Shen
L
L
Lund University, The Wallenberg Laboratory, Department of Clinical Chemistry, University Hospital, Malmö, S-205 02 Malmö, Sweden.
Dahlbäck
B
B
Villoutreix
B O
BO
D020016:Activated Protein C Resistance / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D000925:Anticoagulants / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D002384:Catalysis; D002417:Cattle; D004351:Drug Resistance; D004789:Enzyme Activation / Q000187:drug effects; D006493:Heparin / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding / Q000235:genetics; D011486:Protein C / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D018046:Protein C Inhibitor / Q000494:pharmacology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D013329:Structure-Activity Relationship; D013499:Surface Properties; D000515:alpha 1-Antitrypsin / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*
D000925:Anticoagulants; D011486:Protein C; D018046:Protein C Inhibitor; D011994:Recombinant Proteins; D000515:alpha 1-Antitrypsin; D006493:Heparin